Haleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow HLN
Haleon PLC Sponsored ADR (HLN) Altman Z-score
Haleon PLC Sponsored ADR's Altman Z-score for fiscal 2025 is 3.04, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 3.04 | 0.26 |
| FY2024 | 2.78 | 0.06 |
| FY2023 | 2.72 | 0.19 |
| FY2022 | 2.53 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (0.01) | — | −0.01 | |
| Retained earnings / total assets | 0.85 | — | 1.19 | |
| EBIT / total assets | 0.07 | — | 0.24 | |
| Market value of equity / total liabilities | 2.13 | — | 1.28 | |
| Sales / total assets | 0.34 | — | 0.34 | |
| Altman Z-score | Safe zone | 3.04 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 4.27 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| UTHR United Therapeutics Corporation compare | 19.6× |
| NBIX Neurocrine Biosciences, Inc. compare | 7.8× |
| ZTS Zoetis Inc. compare | 5.7× |
| RDY Dr. Reddy's Laboratories Ltd compare | 5.3× |
| HLN Haleon PLC Sponsored ADR | 3.0× |
| ELAN Elanco Animal Health Incorporated compare | 1.3× |
| TAK Takeda Pharmaceutical Co. compare | 1.0× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 0.8× |
| VTRS Viatris Inc. compare | 0.6× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets